The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

Inclusion Criteria: Patients \>18 years old with corticosteroid-resistant or relapsed ITP who had either a platelet count of \<30×10\^9/L or a platelet count of \<50×10\^9/L and clinically significant bleeding. 1. Not achieving a sustained response to therapy with full-dose corticosteroids for a duration of at least 4 weeks or relapsed during the process of corticosteroid tapering or discontinuation; 2. Platelet counts \<30×10\^9/L or platelet counts \< 50×10\^9/L and significant bleeding symptoms (WHO bleeding scale 2 or above); 3. Willing and able to sign written informed consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Secondary ITP (have a known diagnosis of connective tissue diseases, malignancy, active infection, HIV infections or hepatitis B virus or hepatitis C virus infections); 3. Received drugs affecting the platelet counts within 6 months before the screening visit (e.g., chemotherapy, anticoagulants, etc); 4. Severe medical condition (lung, heart, hepatic or renal disorder); 5. Patients who are deemed unsuitable for the study by the investigator. 6. Patients who had hypertension, diabetes mellitus, hyperthyroidism or coronary heart disease.